Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
National Cancer Institute (NCI)
Eli Lilly and Company
M.D. Anderson Cancer Center
Sensei Biotherapeutics, Inc.
University of Alabama at Birmingham
Theratechnologies
SOLTI Breast Cancer Research Group
Salubris Biotherapeutics Inc